Author(s):
|
Zeng, Y.; Tateishi, H.; Cavalcante, R.; Tenekecioglu, E.; Suwannasom, P.; Sotomi, Y.; Collet, C.; Nie, S.; Jonker, H.; Dijkstra, J.; Radu, M.D.; Raber, L.; McClean, D.R.;
Geuns, R.J.M. van
; Christiansen, E.H.; Fahrni, T.; Koolen, J.; Onuma, Y.; Bruining, N.; Serruys, P.W.
|
Subject:
|
Radboudumc 16: Vascular damage RIHS: Radboud Institute for Health Sciences |
Journal title:
|
Jacc. Cardiovascular Imaging
|
Abstract:
|
OBJECTIVES: The aim of this study was to assess calcium growth with fused grayscale intravascular ultrasound (IVUS), IVUS-virtual histology, and optical coherence tomography (OCT) from baseline to 5-year follow-up in patients treated with bioresorbable vascular scaffolds. BACKGROUND: IVUS and OCT have individual strengths in assessing plaque composition and volume. Fusion of images obtained using these methods could potentially aid in coronary plaque assessment. METHODS: Anatomic landmarks and endoluminal radiopaque markers were used to fuse OCT and IVUS images and match baseline and follow-up. RESULTS: Seventy-two IVUS-virtual histology and OCT paired matched cross-sectional in- and out-scaffold segments were fused at baseline and follow-up. In total, 46 calcified plaques at follow-up were detected using the fusion method (33 in-scaffold, 13 out-scaffold), showing either calcium progression (52.2%) or de novo calcifications (47.8%). On OCT, calcification volume increased from baseline to follow-up by 2.3 +/- 2.4 mm(3) (p = 0.001). The baseline virtual histologic tissue precursors of dense calcium at follow-up were necrotic core in 73.9% and fibrous or fibrofatty plaque in 10.9%. In 15.2%, calcium was already present at baseline. Precursors on OCT were lipid pool in 71.2%, fibrous plaque in 4.3%, and fibrocalcific plaque in 23.9%. CONCLUSIONS: The use of OCT and IVUS fusion imaging shows similar calcium growth in- and out-scaffold segments. Necrotic core is the most frequent precursor of calcification. The scaffold resorption process creates a tissue layer that re-caps the calcified plaques. (Absorb Clinical Investigation, Cohort B [ABSORB B]; NCT00856856).
|